Comments

Bolt Biotherapeutics Analyst Ratings

BOLTNASDAQ

Logo brought to you by Benzinga Data

Trade with Public

$5.39

-0.05-0.92%

At close: Dec 15, 4:00 PM EST

$5.80

0.417.61%

After Hours: Dec 12, 8:36 AM EST

Overview News Earnings Dividends

Analyst Ratings

Insider Trades Short Interest Stock Report

Consensus Rating¹

Buy

Highest Price Target¹

$75.00

Lowest Price Target¹

$1.00

Consensus Price Target¹

$15.17

Bolt Biotherapeutics Analyst Ratings and Price Targets | NASDAQ:BOLT | Benzinga

Bolt Biotherapeutics Inc has a consensus price target of $15.17 based on the ratings of 9 analysts. The high is $75 issued by Lake Street on August 15, 2025. The low is $1 issued by Stifel on May 13, 2025. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Lake Street, and Lake Street on October 20, 2025, August 15, 2025, and May 20, 2025, respectively. With an average price target of $28.67 between HC Wainwright & Co., Lake Street, and Lake Street, there's an implied 394.25% upside for Bolt Biotherapeutics Inc from these most-recent analyst ratings.

Analyst Trends and Forecast

Aug

Oct

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

2.6

Hold

Strong Buy

Buy

Hold

Sell

Strong Sell

Analyst Firms Making Recommendations¹

HC Wainwright & Co.

Lake Street

Stifel

Leerink Partners

SVB Leerink

¹calculated from analyst ratings

Analyst Ratings for Bolt Biotherapeutics

					Get Alert
Oct 20, 2025	20.69%	Robert BurnsHC Wainwright & Co. 57%	7	Previous Current Buy	Get Alert
Aug 15, 2025	1193.1%	Chad MesserLake Street 40%	4 75	Previous Buy Current Buy	Get Alert
May 20, 2025	-31.03%	Chad MesserLake Street 40%	4	Previous Initiates Current Buy	Get Alert
May 13, 2025	-82.76%	Stephen WilleyStifel 64%	1 1.25	Previous Hold Current Hold	Get Alert
Mar 25, 2025	—	Edward WhiteHC Wainwright & Co. 47%	—	Previous Neutral Current Neutral	Get Alert
Mar 25, 2025	-78.45%	Stephen WilleyStifel 64%	1.25 1.5	Previous Hold Current Hold	Get Alert
Nov 13, 2024	—	Edward WhiteHC Wainwright & Co. 47%	—	Previous Current Neutral	Get Alert
Aug 15, 2024	—	Edward WhiteHC Wainwright & Co. 47%	—	Previous Current Neutral	Get Alert
May 15, 2024	-82.76%	Daina GrayboschLeerink Partners 45%	1 3	Previous Outperform Current Market Perform	Get Alert
May 15, 2024	—	Soumit RoyJones Trading 55%	—	Previous Buy Current Hold	Get Alert
May 15, 2024	—	Edward WhiteHC Wainwright & Co. 47%	—	Previous Buy Current Neutral	Get Alert
May 15, 2024	-74.14%	Stephen WilleyStifel 64%	1.5 6	Previous Buy Current Hold	Get Alert
May 15, 2024	—	Michael SchmidtGuggenheim 84%	—	Previous Buy Current Neutral	Get Alert
Mar 22, 2024	37.93%	Edward WhiteHC Wainwright & Co. 47%	8 8	Previous Buy Current Buy	Get Alert
Aug 8, 2023	37.93%	Edward WhiteHC Wainwright & Co. 47%	8	Previous Buy Current Buy	Get Alert
Aug 3, 2023	37.93%	Edward WhiteHC Wainwright & Co. 47%	8	Previous Current Buy	Get Alert
Jun 5, 2023	37.93%	Edward WhiteHC Wainwright & Co. 47%	8	Previous Buy Current Buy	Get Alert
May 26, 2023	37.93%	Edward WhiteHC Wainwright & Co. 47%	8	Previous Current Buy	Get Alert
May 12, 2023	-31.03%	Daina GrayboschSVB Leerink 45%	4	Previous Market Perform Current Outperform	Get Alert
May 12, 2023	37.93%	Edward WhiteHC Wainwright & Co. 47%	8	Previous Buy Current Buy	Get Alert
Mar 30, 2023	37.93%	Edward WhiteHC Wainwright & Co. 47%	8	Previous Current Buy	Get Alert
Jan 24, 2023	-48.28%	Matthew HarrisonMorgan Stanley 62%	3 5	Previous Current Equal-Weight	Get Alert

FAQ

What is the target price for Bolt Biotherapeutics (BOLT) stock?

The latest price target for Bolt Biotherapeutics (NASDAQ:BOLT) was reported by HC Wainwright & Co. on October 20, 2025. The analyst firm set a price target for $7.00 expecting BOLT to rise to within 12 months (a possible 20.69% upside). 6 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Bolt Biotherapeutics (BOLT)?

The latest analyst rating for Bolt Biotherapeutics (NASDAQ:BOLT) was provided by HC Wainwright & Co., and Bolt Biotherapeutics their buy rating.

When was the last upgrade for Bolt Biotherapeutics (BOLT)?

The last upgrade for Bolt Biotherapeutics Inc happened on May 12, 2023 when SVB Leerink raised their price target to $4. SVB Leerink previously had a market perform for Bolt Biotherapeutics Inc.

When was the last downgrade for Bolt Biotherapeutics (BOLT)?

The last downgrade for Bolt Biotherapeutics Inc happened on May 15, 2024 when Leerink Partners changed their price target from $3 to $1 for Bolt Biotherapeutics Inc.

When is the next analyst rating going to be posted or updated for Bolt Biotherapeutics (BOLT)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bolt Biotherapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bolt Biotherapeutics was filed on October 20, 2025 so you should expect the next rating to be made available sometime around October 20, 2026.

Is the Analyst Rating Bolt Biotherapeutics (BOLT) correct?

While ratings are subjective and will change, the latest Bolt Biotherapeutics (BOLT) rating was a with a price target of $0.00 to $7.00. The current price Bolt Biotherapeutics (BOLT) is trading at is $5.80, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.